Our Approach to Advocacy

Our advocacy efforts drive systemic change to fix our broken healthcare system and create equitable access to high-quality care for people with schizophrenia and psychosis. Both S&PAA and our sister organization, the Schizophrenia Policy Action Network, conduct advocacy – each with a slightly different approach:

S&PAA

S&PAA leads efforts to educate key stakeholders and build awareness of issues such as specific treatment barriers, the urgent need for new therapies and the discrimination and stigma that block equitable care.

Schizophrenia Policy
Action Network (SPAN)

The Schizophrenia Policy Action Network (SPAN), a 501(c)(4) advocacy organization created as an affiliate of S&PAA, advances policies and legislation to shatter barriers to care for people living with schizophrenia.

S&PAA

S&PAA leads efforts to educate key stakeholders and build awareness of issues such as specific treatment barriers, the urgent need for new therapies and the discrimination and stigma that block equitable care.

Schizophrenia Policy
Action Network (SPAN)

The Schizophrenia Policy Action Network (SPAN), a 501(c)(4) advocacy organization created as an affiliate of S&PAA, advances policies and legislation to shatter barriers to care for people living with schizophrenia.

Schizophrenia Policy
Action Network (SPAN)

The Schizophrenia Policy Action Network (SPAN), a 501(c)(4) advocacy organization created as an affiliate of S&PAA, advances policies and legislation to shatter barriers to care for people living with schizophrenia.

We speak out against dangerous treatment barriers.

Capitol Hill Day to improve treatment access

Letter to FDA to urge clozapine REMS revisions

We convey the voices and needs of our community to drug developers, regulators and healthcare providers.

Patient-Focused Drug Development Meeting

We tackle the threats to treatment innovation to meet the urgent need for new therapies.

SPAA_IRA-Impact-on-Schizophrenia-Report_Cover_web

Schizophrenia Medicines in Jeopardy report

ICER meeting on schizophrenia treatment

Congressional letter to address negative impact of Inflation Reduction Act

Partnership for Chronic Disease webinar on IRA impact